Denosumab as treatment of central giant cell granuloma of the jaws. a scoping review
This study aimed to perform a scoping review of CGCG treated with Denosumab. The research question was: What is Denosumab ’s effectiveness in treating CGCG of the jaws? Studies that used Denosumab as a treatment for CGCGs in the jaws were selected following PRISMA-ScR guidelines, using Pubmed/Medline, Scopus, and Springer Link databases, among others. Demographics, clinical information, dosing, efficacy, adverse drug reactions (ADRs), and imaging tests used to assess the evolution of the lesions were extracted. Twenty-one studies were selected. Sixty patients with a mean age of 23.2 years were treated with Denosumab, 42...
Source: Oral and Maxillofacial Surgery - March 28, 2024 Category: ENT & OMF Source Type: research
Efficacy of denosumab against osteoporosis determined using quantitative computed tomography in treatment-na ïve male patients with ankylosing spondylitis: case series of six patients
Scand J Rheumatol. 2024 Mar 26:1-3. doi: 10.1080/03009742.2024.2316960. Online ahead of print.NO ABSTRACTPMID:38529827 | DOI:10.1080/03009742.2024.2316960 (Source: Scandinavian Journal of Rheumatology)
Source: Scandinavian Journal of Rheumatology - March 26, 2024 Category: Rheumatology Authors: S H Kim S-H Lee R Song Source Type: research
Efficacy of denosumab against osteoporosis determined using quantitative computed tomography in treatment-na ïve male patients with ankylosing spondylitis: case series of six patients
Scand J Rheumatol. 2024 Mar 26:1-3. doi: 10.1080/03009742.2024.2316960. Online ahead of print.NO ABSTRACTPMID:38529827 | DOI:10.1080/03009742.2024.2316960 (Source: Scandinavian Journal of Rheumatology)
Source: Scandinavian Journal of Rheumatology - March 26, 2024 Category: Rheumatology Authors: S H Kim S-H Lee R Song Source Type: research
Efficacy of denosumab against osteoporosis determined using quantitative computed tomography in treatment-na ïve male patients with ankylosing spondylitis: case series of six patients
Scand J Rheumatol. 2024 Mar 26:1-3. doi: 10.1080/03009742.2024.2316960. Online ahead of print.NO ABSTRACTPMID:38529827 | DOI:10.1080/03009742.2024.2316960 (Source: Scandinavian Journal of Rheumatology)
Source: Scandinavian Journal of Rheumatology - March 26, 2024 Category: Rheumatology Authors: S H Kim S-H Lee R Song Source Type: research
Efficacy of denosumab against osteoporosis determined using quantitative computed tomography in treatment-na ïve male patients with ankylosing spondylitis: case series of six patients
Scand J Rheumatol. 2024 Mar 26:1-3. doi: 10.1080/03009742.2024.2316960. Online ahead of print.NO ABSTRACTPMID:38529827 | DOI:10.1080/03009742.2024.2316960 (Source: Scandinavian Journal of Rheumatology)
Source: Scandinavian Journal of Rheumatology - March 26, 2024 Category: Rheumatology Authors: S H Kim S-H Lee R Song Source Type: research
Efficacy of denosumab against osteoporosis determined using quantitative computed tomography in treatment-na ïve male patients with ankylosing spondylitis: case series of six patients
Scand J Rheumatol. 2024 Mar 26:1-3. doi: 10.1080/03009742.2024.2316960. Online ahead of print.NO ABSTRACTPMID:38529827 | DOI:10.1080/03009742.2024.2316960 (Source: Scandinavian Journal of Rheumatology)
Source: Scandinavian Journal of Rheumatology - March 26, 2024 Category: Rheumatology Authors: S H Kim S-H Lee R Song Source Type: research
Efficacy of denosumab against osteoporosis determined using quantitative computed tomography in treatment-na ïve male patients with ankylosing spondylitis: case series of six patients
Scand J Rheumatol. 2024 Mar 26:1-3. doi: 10.1080/03009742.2024.2316960. Online ahead of print.NO ABSTRACTPMID:38529827 | DOI:10.1080/03009742.2024.2316960 (Source: Scandinavian Journal of Rheumatology)
Source: Scandinavian Journal of Rheumatology - March 26, 2024 Category: Rheumatology Authors: S H Kim S-H Lee R Song Source Type: research
Real-World Evaluation of Primary Versus Secondary Prevention of Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer
CONCLUSION: A majority of patients with mCRPC never receive BTAs prior to first SRE, despite universal access and availability of these agents in Ontario. These results highlight an opportunity to improve outcomes by emphasizing early introduction of BTA in patients with mCRPC being started on systemic therapy.PMID:38527096 | DOI:10.1093/oncolo/oyae036 (Source: The Oncologist)
Source: The Oncologist - March 25, 2024 Category: Cancer & Oncology Authors: William J Phillips Fred Saad Jennifer Leigh Alborz Jooya Colleen Webber Scott Morgan Robert MacRae Jean-Marc Bourque Peter Tanuseputro Michael Ong Source Type: research
Recurrent severe hypocalcemia following chemotherapy regimen changes in advanced breast cancer: two case reports
ConclusionsWe observed two cases of recurrent severe hypocalcemia in patients with advanced breast cancer and bone metastases after modifications to their therapy regimens. These cases differed from the typical hypocalcemia induced by bone-modifying agents. It is possible that antitumor drugs affect calcium and bone metabolism associated with bone metastases. While these cases are rare, it is crucial for oncologists to be aware of hypocalcemia not only at the initiation of bone-modifying agents but also throughout the entire antitumor therapy, as hypocalcemia can lead to fatal outcomes. (Source: Journal of Medical Case Reports)
Source: Journal of Medical Case Reports - March 25, 2024 Category: General Medicine Source Type: research
Long-term effects of denosumab on bone mineral density and turnover markers in patients undergoing hemodialysis
ConclusionThe study showed long-term suppression of TRACP-5b and BAP levels and sustaining BMD after denosumab administration over an extended period in patients undergoing hemodialysis. (Source: Journal of Bone and Mineral Metabolism)
Source: Journal of Bone and Mineral Metabolism - March 21, 2024 Category: Orthopaedics Source Type: research
Exploring epigenetic strategies for the treatment of osteoporosis
Mol Biol Rep. 2024 Mar 8;51(1):398. doi: 10.1007/s11033-024-09353-4.ABSTRACTThe worldwide trend toward an aging population has resulted in a higher incidence of chronic conditions, such as osteoporosis. Osteoporosis, a prevalent skeletal disorder characterized by decreased bone mass and increased fracture risk, encompasses primary and secondary forms, each with distinct etiologies. Mechanistically, osteoporosis involves an imbalance between bone resorption by osteoclasts and bone formation by osteoblasts. Current pharmacological interventions for osteoporosis, such as bisphosphonates, denosumab, and teriparatide, aim to mo...
Source: Molecular Biology Reports - March 7, 2024 Category: Molecular Biology Authors: Sun-Ju Yi Jaeho Lim Kyunghwan Kim Source Type: research
Cancer treatment-induced bone loss
Korean J Intern Med. 2024 Mar 5. doi: 10.3904/kjim.2023.386. Online ahead of print.ABSTRACTCancer treatment-induced bone loss (CTBL) is associated with anti-tumor treatments, including endocrine therapies, chemotherapeutic treatments, radiotherapy, glucocorticoids, and tyrosine kinase inhibitors. Osteoporosis, characterized by the loss of bone mass, can increase the risk of fractures, leading to mortality and long-term disability, even after cancer remission. Cancer and osteoporosis have marked clinical and pathogenetic similarities. Both have a multifactorial etiology, affect the geriatric population, and markedly influen...
Source: The Korean Journal of Internal Medicine - March 5, 2024 Category: Internal Medicine Authors: Yong Jun Choi Source Type: research
Cancer treatment-induced bone loss
Korean J Intern Med. 2024 Mar 5. doi: 10.3904/kjim.2023.386. Online ahead of print.ABSTRACTCancer treatment-induced bone loss (CTBL) is associated with anti-tumor treatments, including endocrine therapies, chemotherapeutic treatments, radiotherapy, glucocorticoids, and tyrosine kinase inhibitors. Osteoporosis, characterized by the loss of bone mass, can increase the risk of fractures, leading to mortality and long-term disability, even after cancer remission. Cancer and osteoporosis have marked clinical and pathogenetic similarities. Both have a multifactorial etiology, affect the geriatric population, and markedly influen...
Source: The Korean Journal of Internal Medicine - March 5, 2024 Category: Internal Medicine Authors: Yong Jun Choi Source Type: research
Cancer treatment-induced bone loss
Korean J Intern Med. 2024 Mar 5. doi: 10.3904/kjim.2023.386. Online ahead of print.ABSTRACTCancer treatment-induced bone loss (CTBL) is associated with anti-tumor treatments, including endocrine therapies, chemotherapeutic treatments, radiotherapy, glucocorticoids, and tyrosine kinase inhibitors. Osteoporosis, characterized by the loss of bone mass, can increase the risk of fractures, leading to mortality and long-term disability, even after cancer remission. Cancer and osteoporosis have marked clinical and pathogenetic similarities. Both have a multifactorial etiology, affect the geriatric population, and markedly influen...
Source: The Korean Journal of Internal Medicine - March 5, 2024 Category: Internal Medicine Authors: Yong Jun Choi Source Type: research
Cancer treatment-induced bone loss
Korean J Intern Med. 2024 Mar 5. doi: 10.3904/kjim.2023.386. Online ahead of print.ABSTRACTCancer treatment-induced bone loss (CTBL) is associated with anti-tumor treatments, including endocrine therapies, chemotherapeutic treatments, radiotherapy, glucocorticoids, and tyrosine kinase inhibitors. Osteoporosis, characterized by the loss of bone mass, can increase the risk of fractures, leading to mortality and long-term disability, even after cancer remission. Cancer and osteoporosis have marked clinical and pathogenetic similarities. Both have a multifactorial etiology, affect the geriatric population, and markedly influen...
Source: The Korean Journal of Internal Medicine - March 5, 2024 Category: Internal Medicine Authors: Yong Jun Choi Source Type: research
